Pfizer Inc. (PFE)
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
Pfizer (PFE) closed at $25.62 in the latest trading session, marking a +1.51% move from the prior day.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
Shares of Pfizer ( NYSE: PFE ) surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.
Pfizer: Options Activity Speaks Bullish
The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and innovation, with recent pipeline successes as catalysts. Despite macro risks and ROIC below historical averages, PFE stock's 52% upside to fair value and compelling yield make it a rare value opportunity.
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pfizer Could Be The Turnaround Story In The Pharmaceutical Space
Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep discounts on P/E, EV/EBITDA, and P/B, with a strong 8.2% FCF yield and sector-leading 7% dividend. Risks include patent cliffs, U.S. drug price regulation, and R&D setbacks, but robust margins and pipeline support long-term growth.
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding its cost-savings program to a massive $7.7 billion by 2027, aiming to create a powerful EPS growth story despite flat revenues. Pfizer's non-COVID portfolio is firing on all cylinders, with key drugs like Nurtec and Padcev showing robust double-digit growth, proving underlying business health.
